BioElectronics Corporation (OTC: BIEL) announced the commercial launch of its ActiPatch device in Taiwan through distributor Aphrodite Medical Group, marking a significant expansion of drug-free pain management options in the region. The move positions ActiPatch as a non-pharmaceutical alternative amid growing demand for safe, effective pain relief.
ActiPatch is a US FDA-cleared medical device that uses pulsed shortwave therapy to modulate pain at the peripheral nerve level. Each device provides up to 720 hours of continuous therapy and can be worn during sleep, offering a practical solution for patients seeking to avoid opioids or other pain medications.
Kelly Whelan, CEO of BioElectronics Corporation, emphasized the strategic importance of the partnership. "The appointment of Aphrodite Medical Group establishes a strong commercial foundation for ActiPatch in Taiwan. Their clinical infrastructure and commitment to advanced patient care make them a capable partner to introduce and scale this therapy in a meaningful way."
The initial shipment of units has been completed, with a coordinated market launch planned for Q2 2026. The rollout will initially focus on musculoskeletal pain management, with potential expansion into other clinical applications over time. Aphrodite Medical Group, a well-established healthcare provider with a broad clinical footprint in Taiwan, will lead physician engagement and patient access initiatives.
Yang Pei-Hsien, Vice President of Aphrodite Medical Group, expressed enthusiasm for the product. "We are pleased to bring ActiPatch to Taiwan as part of our commitment to delivering innovative, patient-centered therapies. This technology aligns with the growing demand for safe, effective, and drug-free pain management options."
The Taiwan launch reinforces BioElectronics' strategy to expand through high-quality distribution partnerships in key markets while maintaining focus on clinically validated, scalable bioelectronic therapies. The company's portfolio also includes RecoveryRx, another FDA-cleared device using similar technology to support recovery.
This development underscores a broader shift toward non-pharmacological interventions in pain management, particularly as concerns over opioid addiction and side effects from long-term medication use persist. By offering a drug-free alternative, ActiPatch could appeal to patients and healthcare providers looking for safer options.
